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Introduction: To estimate the cost-effectiveness of first-line cispla-
tin/pemetrexed (Cis/Pem) compared with cisplatin/gemcitabine
(Cis/Gem), carboplatin/paclitaxel (Carb/Pac), and carboplatin/pacli-
taxel/bevacizumab (Carb/Pac/Bev) in patients with advanced non-
small cell lung cancer (NSCLC), particularly in those with nonsqua-
mous cell histology (i.e., adenocarcinoma, large cell carcinoma, or
histology not otherwise specified).
Methods: A semi-Markov model was developed to compare the
2-year impact of Cis/Pem to three other first-line regimens from the
U.S. payer perspective. Data from the randomized controlled clinical
trial of Cis/Pem versus Cis/Gem and a mixed treatment comparison
model (no head-to-head data were available for the Cis/Pem to
Carb/Pac or Carb/Pac/Bev comparisons) provided clinical inputs.
Medicare reimbursement rates were used to determine drug costs. A
retrospective claims database analysis was used to obtain estimates
of other direct NSCLC-related costs.
Results: In all patients with advanced NSCLC regardless of histo-
logic subtype, using Cis/Pem as first-line chemotherapy led to an
incremental cost per life-year gained (LYG) of $104,577 for Cis/
Pem to Cis/Gem and $231,291 for Cis/Pem to Carb/Pac. In the
prespecified subset of patients with nonsquamous cell histology, the
incremental cost per LYG was $83,537 for Cis/Pem to Cis/Gem and
$178,613 for Cis/Pem to Carb/Pac. The incremental cost per LYG
for Carb/Pac/Bev to Cis/Pem was more than $300,000.
Conclusions: Compared with commonly used and reimbursed reg-
imens for first-line chemotherapy in advanced NSCLC, Cis/Pem
may be considered cost-effective, particularly in patients with
nonsquamous cell histology. This analysis emphasizes the impor-
tance of histology in identifying the appropriate patient for Cis/Pem
first-line chemotherapy.
Key Words: Pemetrexed, Advanced NSCLC, First line, Cost-
effectiveness.
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In the United States, more than 215,000 people are estimatedto develop lung cancer in 2008, with 87% classified as
having non-small cell lung cancer (NSCLC).1 The prognosis
of these patients is poor with less than 40% of patients
surviving at 1 year postdiagnosis.2
In patients with advanced (stage IIIB/IV) NSCLC,
clinical guidelines recommend the use of two-drug combina-
tion regimens (doublets) as first-line therapy.3–5 Regimens
combining a platinum with third-generation agents, such as
taxanes, vinorelbine, camptothecin analogs, or gemcitabine,
have demonstrated improved survival compared with plati-
num doublets containing second-generation agents (e.g., vin-
desine, etoposide, and ifosfamide).6 However, there is little
differentiation among these third-generation platinum doublet
regimens in terms of survival benefit with the main distinc-
tion coming from differences in adverse event profiles.2,7,8
Doublets containing paclitaxel or gemcitabine plus a
platinum are effective regimens for the first-line treatment of
advanced NSCLC.7,9 More recently, a triplet regimen of
carboplatin/paclitaxel/bevacizumab (Carb/Pac/Bev) demon-
strated a survival benefit versus Carb/Pac as first-line therapy in
patients with stage III/IV NSCLC with nonsquamous histolo-
gy.10 The risk of adverse events, particularly bleeding or throm-
botic disorders, limits the recommended use of the triplet regi-
men to patients with nonsquamous histology, good performance
status, lack of brain metastases, and no history of hemoptysis.5
These three regimens (Cis/Gem, Carb/Pac, and Carb/Pac/Bev)
are considered to be relevant comparators for first-line therapy in
the treatment of advanced NSCLC in the U.S. market.
Pemetrexed is an antifolate antineoplastic agent cur-
rently approved in the United States as a single-agent second-
line therapy for the treatment of patients with locally ad-
vanced or metastatic NSCLC.11 In a recent phase III clinical
trial, cisplatin and pemetrexed (Cis/Pem) demonstrated non-
inferior efficacy compared with Cis/Gem as first-line treat-
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ment in patients with locally advanced or metastatic NSCLC.
A median survival time of 10.3 months was reported for both
regimens (Figure 1).12 Hematologic and nonhematologic tox-
icities, with the exception of nausea, significantly favored
Cis/Pem. Additionally, compared with Cis/Gem, patients
treated with Cis/Pem used fewer medical resources including
significant reductions in the need for transfusions and the
administration of erythropoietic or granulocyte colony-stim-
ulating factors (p  0.05 for each comparison).12,13
Histologic subtype has been identified as a main pre-
dictive factor for response rate in patients with advanced
NSCLC,14 though it has not reliably predicted survival.6 A
prespecified subset analysis from the Scagliotti et al. trial
demonstrated statistically superior overall survival time for
Cis/Pem compared with Cis/Gem (median 11.8 versus 10.4
months, p 0.005) in patients with advanced NSCLC having
adenocarcinoma or large cell histology (Figure 1). Consistent
with the findings in the overall population, in patients with
advanced nonsquamous NSCLC (i.e., adenocarcinoma, large
cell histology, or histology not otherwise specified), Cis/Pem
was associated with significantly lower rates of grade 3/4
hematologic toxicities compared with Cis/Gem (p  0.05 for
each comparison). In this subset of patients, Cis/Pem also led
to significantly lower use of transfusions and erythropoietic
or granulocyte colony stimulating factors (p  0.05 for each
comparison) compared with Cis/Gem.13
The study by Scagliotti et al.15,16 is the first phase III
study to report survival differences among platinum doublets
based on histology. Pemetrexed inhibits thymidylate synthase
(TS) and other folate-dependent enzymes. Although not dem-
onstrated in randomized, controlled clinical trials, high ex-
pression of TS has been found to correlate with reduced
sensitivity to pemetrexed.17,18 Thus, it is hypothesized that
the differential activity of Cis/Pem may be related to a
differential expression of TS in different histotypes of
NSCLC.12
Cis/Pem has demonstrated similar or better efficacy,
better tolerability, and a reduced need for certain medical
resources compared with Cis/Gem as first-line therapy in
patients with advanced NSCLC. In those with nonsquamous
cell histology, outcomes are further improved with Cis/Pem
compared with Cis/Gem. However, in addition to demonstrat-
ing efficacy, chemotherapy regimens must also demonstrate
cost-effectiveness compared with other regimens commonly
used in clinical practice. Improved cost-effectiveness is recog-
FIGURE 1. Overall survival in patients with stage IIIB/IV
NSCLC by histologic subtype treated with first-line cisplatin
and pemetrexed (Cis/Pem) versus cisplatin/gemcitabine (Cis/
Gem). Cis/Pem demonstrated noninferior efficacy compared
with Cis/Gem as first-line treatment in patients with locally
advanced or metastatic NSCLC. A prespecified subset analysis
demonstrated statistically superior overall survival time for
Cis/Pem compared with Cis/Gem in patients with adenocar-
cinoma or large cell histology. *Nonsquamous refers to ade-
nocarcinoma and large cell carcinoma. CG, cisplatin/gemcit-
abine; CI, confidence interval; CP, cisplatin/pemetrexed; HR,
hazard ratio; NSCLC, non-small cell lung cancer. Reprinted
with permission. © 2008 American Society of Clinical Oncol-
ogy. All rights reserved. Scagliotti GV, Parikh P, von Pawel J,
et al. Phase III study comparing cisplatin plus gemcitabine
with cisplatin plus pemetrexed in chemotherapy-naive pa-
tients with advanced-stage non–small-cell lung cancer. J Clin
Oncol 2008;26:3543–3551.
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nized by the American Society for Clinical Oncology as one of
four important outcomes in developing guidelines for drug use.19
The primary objective of this study was to conduct a
cost-effectiveness analysis comparing the costs and the ben-
efits of first-line Cis/Pem therapy versus Cis/Gem. Although
there are no phase III trials comparing Cis/Pem to Carb/Pac
and Carb/Pac/Bev in patients with advanced NSCLC, these
two additional regimens were included in the analysis as a
secondary objective as they are frequently used regimens in
clinical practice. Because of the increasing importance of
histology in identifying the most appropriate candidates for
specific first-line therapies, this cost-effectiveness analysis
incorporates patient histology by defining two different pa-
tient populations: (1) patients with advanced nonsquamous
NSCLC and (2) all patients with advanced NSCLC (either
squamous or nonsquamous cell histology).
MATERIALS AND METHODS
Model Structure
A semi-Markov state transition model was developed to
compare the short-term impact of Cis/Pem to three first-line
chemotherapy regimens including Cis/Gem, Carb/Pac, and
Carb/Pac/Bev (Table 1). A semi-Markov structure was cho-
sen to model benefits and costs at a group level rather than at
the individual patient level. The comparators were selected
based on market research and reflected regimens commonly
used in clinical practice in the United States. A U.S. payer
perspective was used; therefore, only direct health care costs
were included in the model.
The model base case included patients with stage
IIIB/IV NSCLC with nonsquamous cell histology. Compar-
ators for this analysis included Cis/Gem, Carb/Pac, and Carb/
Pac/Bev. Cost-effectiveness data for this patient population
are presented in detail within this article. A second patient
population included all patients with advanced NSCLC, re-
gardless of histologic subtype. Patients in the second patient
population represented the intent-to-treat population from the
head-to-head clinical trial of Cis/Pem versus Cis/Gem. Be-
cause Carb/Pac/Bev is not indicated in patients with advanced
NSCLC with squamous cell histology, only Cis/Gem and
Carb/Pac were included as comparators when evaluating all
patients with advanced NSCLC.
The model used estimates of treatment and NSCLC-
related cost and clinical outcomes attributable to the use of
each regimen in the 2 years after initiation of first-line
therapy. In terms of costs and life-years (and thus cost-
effectiveness ratios between regimens), a 2-year timeframe
was considered to be most representative because most pa-
tients have died, and there is little difference between regi-
mens in terms of remaining costs and life-years not yet
accumulated. One-year and 6-month results are also available
to describe the impact on costs and outcomes.
Primary model outputs included expected costs and
life-year gained (LYG) during 2 years by a person initiating
first-line chemotherapy for advanced NSCLC. Incremental
cost-effectiveness ratios (ICERs) and incremental cost-utility
ratios comparing Cis/Pem with the three comparators were
also calculated.
The model was based on four health states that could
occur during first-line chemotherapy representing the stan-
dard oncology classifications of complete response, partial
response, stable disease, and progressive disease (Figure 2).
The model is initiated with a cohort of patients with stage
IIIB/IV NSCLC starting a prescribed course of six 3-week
cycles of first-line chemotherapy. After completing or dis-
continuing first-line chemotherapy, health states included
second-line chemotherapy, stable disease without chemother-
apy, progressive disease without chemotherapy, and end-of-
life care. For the triplet of Carb/Pac/Bev, there was an
additional bevacizumab monotherapy maintenance state. Fi-
TABLE 1. General Description of the Base Case Model
Parameter Base Case Value
Study therapies and dose
per 3-wk cycle
Cis/Pem—Cis: 75 mg/m2 with 1 treatment
per cycle, Pem: 500 mg/m2 with 1
treatment per cycle
Cis/Gem—Cis: 75 mg/m2 with 1 treatment
per cycle, Gem: 1250 mg/m2 with 2
treatments per cycle
Carb/Pac—Carb: 100 mg per AUC
(assumed to be 6 mg/mL min) with 1
treatment per cycle, Pac: 200 mg/m2 with
1 treatment per cycle
Carb/Pac/Bev—Carb: 100 mg per AUC
(assumed to be 6 mg/mL min) with 1
treatment per cycle, Pac: 200 mg/m2 with
1 treatment per cycle, and Bev: 15 mg/kg
with 1 treatment per cycle
Bev maintenance—15 mg/kg with 1
treatment per cycle
Patient population Chemotherapy-naïve patients with stage
IIIB/IV NSCLC with nonsquamous cell
histology (i.e., adenocarcinoma, large cell
carcinoma, or not otherwise specified).
Patient characteristics were representative
of the head-to-head phase 3 clinical trial
of Cis/Pem versus Cis/Gem12 and
included an ECOG performance status of
0 or 1, median age of 61 yr, 70% male,
and 78% white.
Body surface area (BSA) 1.8 m2 for all regimens
Model perspective U.S. payer
Time horizon 2 yr
Benefits Tumor response rate
Progression rate
Cost per life-year gained
Cost per quality-adjusted life-year gained
Costs NSCLC-related direct health care costs
including chemotherapy, costs of
premedication, administration of
chemotherapy, laboratory monitoring,
treating common adverse events,
subsequent therapies, direct care for
disease-related morbidity, and end-of-life
care
Discount rate None
AUC, target area under the concentration versus time curve in mg/mL min; ECOG,
Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
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nally, there was a death state, which can be reached from all
other states (Figure 3). Treatment cycle lengths after discon-
tinuation or completion of first-line therapy were 3 weeks
until week 18 for those who terminated initial treatment early,
a transition cycle from week 18 until 6 months and then three
6-month cycles, after which most of the cohort will have died.
Model Inputs
Clinical Inputs
Clinical outcomes of response and progression rates
were included in the model. Data for Cis/Pem and Cis/Gem
were obtained from the intent-to-treat population and the
prespecified subset of patients with nonsquamous histology
from a head-to-head clinical trial in patients with advanced
NSCLC.12 Transition rates, or the probability of moving
from one disease state to another, were calculated by
fitting to targeted response, progression, and death likeli-
hoods obtained for the Cis/Pem and Cis/Gem regimens
from survival curves.
Because head-to-head clinical trial data were not avail-
able comparing the efficacy of Carb/Pac or Carb/Pac/Bev
against Cis/Pem, data such as differential survival and re-
sponse rates for these two regimens were obtained from a
mixed treatment comparison model of Cis/Pem versus Carb/
Pac and versus Carb/Pac/Bev.20 Survival and response rate
targets for Carb/Pac and Carb/Pac/Bev were calculated by
applying relative risks obtained from the indirect comparison.
Survival and response probabilities used the calculated esti-
mates for each regimen rather than assuming that those
without statistically significant differences were equivalent.
The model default utility values were calculated using
an algorithm by Nafees et al.21 (Table 2) as this was the only
report for advanced NSCLC that considered both tumor
response status and toxicities. For utility calculations, neu-
tropenia and fatigue were considered to be serious side
effects, and diarrhea and vomiting were considered mild side
effects. No differences in disutility from mild side effects
were assumed among regimens.
Cost Inputs
The model used advanced NSCLC-related direct health
care costs including the costs of premedication, administra-
tion of chemotherapy, laboratory monitoring, treating com-
mon adverse events, subsequent therapies, direct care for
disease-related morbidity, and end-of-life care (Table 3).
Nonmedical or indirect costs were not included in the model.
Drug costs for the first-line chemotherapy regimens
were based on maximum allowable Medicare reimbursement
FIGURE 2. Tree diagram for first-
line chemotherapy regimens. The
cost-effectiveness model was based
on four health states including
complete response, partial re-
sponse, stable disease, and pro-
gressive disease. Bev, bevacizumab;
Carb, carboplatin; Chemo, chemo-
therapy; Cis, cisplatin; Gem, gem-
citabine; NSCLC, non-small cell
lung cancer; Pac, paclitaxel; Pem,
pemetrexed.
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rates and average doses.22 Other direct NSCLC-related costs
were obtained from an analysis of the PharMetrics paid
claims database (PharMetrics, Inc., Watertown, MA), which
included data for 74,053 patients with a possible lung cancer
diagnosis from January 2002 to September 2007. More than
30 million service lines from institutional, professional, and
pharmacy claims representing nearly 100 health plans in the
United States were analyzed. A feature of the PharMetrics
database is the inclusion of claims grouped into episodes of
illness and a code representing the category of illness or
episode treatment group (ETG). To estimate other direct
NSCLC-related costs, ETG 0401, representing malignant
neoplasm of the pulmonary system without surgery, was
combined with the diagnostic code ICD9 162x, representing
malignant neoplasm of trachea, bronchus, and lung. Because
ETG 0401 includes only individuals who did not receive
surgery, this helped to ensure that any chemotherapy received
was not second-line or adjuvant to a prior surgical therapy.
Standard data cleansing procedures were used in eval-
uating the administrative claims data. Either carboplatin or
cisplatin were considered to be acceptable platinum agents.
Service lines were searched for the earliest date of adminis-
tration of first-line antineoplastic regimens associated with a
diagnosis of lung cancer and ETG 0401. This date and the
antineoplastics administered on this date were recorded on
12,223 patient records.
Patients were excluded from the analysis if: (1) they
received first-line chemotherapies other than docetaxel/plati-
FIGURE 3. Tree diagram for
health states after completion of
first-line chemotherapy regimens.
The model is initiated with a co-
hort of patients with stage IIIB/IV
NSCLC starting a prescribed course
of first-line chemotherapy. After
completing or discontinuing first-
line chemotherapy, health states
included second-line chemother-
apy, stable disease without chemo-
therapy, progressive disease with-
out chemotherapy, and end-of-life
care. For the triplet of carboplatin/
paclitaxel/bevacizumab (Carb/Pac/
Bev), there was an additional
bevacizumab monotherapy mainte-
nance state. Finally, there was a
death state, which can be reached
from all other states. Bev, bevaci-
zumab; Carb, carboplatin; Chemo,
chemotherapy; NSCLC, non-small
cell lung cancer; Pac, paclitaxel.
TABLE 2. Utility Values for Health States Based on Presence of Side Effects and First-Line Chemotherapy Used in the
Cost-Effectiveness Model
Health States No Treatment
Mild SE
Cis/Pem
Mild SE
Cis/Gem
Mild SE
Carb/Pac
Mild SE
Carb/Pac/Bev Serious SE Second Line
Progressive disease 0.47 0.48 0.48 0.48 0.48 0.31 0.43
Stable disease 0.65 0.56 0.56 0.56 0.56 0.49 0.54
Partial response 0.67 0.58 0.58 0.58 0.58 0.51
Complete response 0.85 0.75 0.75 0.75 0.75 0.68
End of life 0.35 0.25 0.25 0.25 0.25 0.18
Death 0.00 0.00 0.00 0.00 0.00 0.00
Source: Based on data from Nafees et al.21
Bev, bevacizumab; Carb, carboplatin; Cis, cisplatin; Gem, gemcitabine; Pem, pemetrexed; SE, side effect.
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num or those used in the model (Bev/Pac/platinum, Gem/
platinum, Pac/platinum, or Pem/platinum); (2) a treatment for
lung cancer was billed before receipt of first chemotherapy;
(3) a diagnosis of other cancers was made between 2 years
and 3 months before the first chemotherapy; (4) the first
chemotherapy occurred within the first month of health plan
eligibility; or (5) the date of first chemotherapy was before
January 1, 2002, to eliminate patients who received paclitaxel
before its patent expiration. After applying exclusion criteria,
the cost analysis was based on data from 3348 patients. The
majority of patients identified (85%) received a taxane/plat-
inum doublet as first-line therapy. Very few patients received
the triplet of Bev/Pac/platinum (2.5%) or Pem/platinum
(0.5%) as first-line therapy, which was not unexpected, as
Pem/platinum was not approved for use as first-line therapy
over the time period of the data analyzed, and Bev/Pac/
platinum was not approved for first-line use until October
2006.23 Although Bev/Pac/platinum is now frequently used in
the United States, its use was limited during the years in-
cluded in the database analysis.
The costs of all drugs included in the initial chemo-
therapy regimen that were charged in the first 22 weeks of
treatment were considered first line. The remainder of the
antineoplastic costs was included as second-line therapy.
The 22-week period was used to allow for delays in
reporting the actual utilization and to ensure all first-line
costs were excluded from the second-line costs. Costs asso-
ciated with ICD9 162x or ETG 0401 were accumulated for
each patient from the date of first chemotherapy until end of
treatment, loss of insurance eligibility, or death, which ever
occurred first.
Costs incurred could be attributed to more than 2800
different procedure and drug codes. A clinical consultant was
used to group and distribute costs across seven model cost
inputs including: (1) administration or monitoring of initial
chemotherapy, (2) managing mild side effects of initial che-
motherapy, (3) managing and treatment of serious side effects
of initial chemotherapy, (4) second-line chemotherapy in-
cluding administration, monitoring, and managing of side
effects, (5) ongoing management of stable or partially remit-
ted NSCLC (postchemotherapy), (6) ongoing management of
progressive NSCLC (postchemotherapy), and (7) end-of-life
treatment (Table 3). In the base case, the costs for all but the
first two model cost inputs stated earlier were calculated from
a weighted average of all the five first-line regimens de-
scribed earlier and, thus, were assumed to be the same for all
four regimens included in the model.
The difference among regimens in serious side-effect
costs is due to differences in the rate of serious adverse
events. A serious adverse event was defined as any adverse
event that resulted in one of the following outcomes or was
significant for any other reason: death, initial or prolonged
inpatient hospitalization, a life-threatening experience, per-
sistent or significant disability/incapacity, or a congenital
anomaly/birth defect. There was not a suitable methodology
for distinguishing between types of adverse events in the
claims database analysis; thus, the average cost of all events
over all therapies was calculated. Based on the results of the
claims database analysis, it was assumed that the cost for
treating a particular serious adverse event associated with
first-line chemotherapy was the same across all four regimens
of the model. Similarly, the cost of all second-line chemo-
therapy (e.g., docetaxel, erlotinib, gemcitabine, and pem-
etrexed) and treatment of associated adverse events were
considered to be the same across all four first-line treatment
regimens. In clinical practice, costs of second-line chemo-
therapy would not be equivalent across all four first-line
regimens, because selection of a second-line regimen would
be driven by the first-line regimen used. A conservative
approach was taken to avoid biasing cost estimates against
Carb/Pac and Cis/Gem, which may receive pemetrexed as a
second-line regimen, whereas the Cis/Pem first-line regimen
would typically receive a less expensive second-line regimen
such as docetaxel.
Because of the short time horizon of the model and
because most of the costs and benefits of first-line therapy
were incurred within the first year of therapy, no discounting
was done for the base case analysis. Discounting at 3% and
5% was performed in the sensitivity analysis.
Model Assumptions
Assumptions are inherent in any economic model due
to the model structure, limitations in available data, and the
need to simplify the model to deliver results that are under-
standable and reflect actual clinical practice. Appendix pre-
sents the assumptions included in this cost-effectiveness
model.
TABLE 3. Model Inputs for Treatment Cost per 3-Week
Cycle (U.S.$)
Component
Cis/
Pema
Cis/
Gem
Carb/
Pac
Carb/Pac/
Bev
Treatment only 4614 3198 248 6568
Administration and monitoring 2235 3159 3129 3181
Mild side effects 89 156 135 135
Treatment plus administration
and mild side effects
6938 6513 3512 9884
Serious side effects (per event) 26,299 26,299 26,299 26,299
Treatment plus administration
and serious side effects
33,148 32,656 29,676 36,048
Second-line treatment 6568 6568 6568 6568
Second-line side effect (mean) 2267 2267 2267 2267
Second-line with side effect
treatment
8835 8835 8835 8835
Second-line 6-mo inclusive 47,671 47,671 47,671 47,671
Bev maintenance treatment 6321
Bev maintenance
administration
1326
Bev maintenance treatment
and administration
7647
a Assumes that 93% of patients received pemetrexed through a 500mg vial and 7%
received pemetrexed through a 100mg vial.
Bev, bevacizumab; BSA, body surface area; Carb, carboplatin; Cis, cisplatin; Gem,
gemcitabine; Pem, pemetrexed.
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Sensitivity Analyses
A series of one-way sensitivity analyses were con-
ducted to estimate the importance of uncertainty in the
modeled input values on the cost-effectiveness of the first-
line chemotherapies. Cost inputs were increased and de-
creased by 50%. The assumptions of equal costs for serious
side effects and second-line treatment were examined by
varying these costs by first-line treatment. The assumption of
unequal costs for mild side effects was also tested by making
these costs equal across regimens. Adverse event rates were
increased and decreased by 50%. Progression and response
transition rates while on first-line chemotherapy were varied
from 50 to 200% of their original values. Discounting sec-
ond-year costs and life-years up to 5% were also evaluated.
In the model base case, it was assumed that 93% of
patients in the Cis/Pem arm received pemetrexed through a
500-mg vial and 7% received pemetrexed through a 100-mg
vial. The impact of increasing the proportion of patients
receiving pemetrexed through the 100 mg vial was evaluated
in sensitivity analyses.
There was an implied assumption in the model that
almost all patients who responded to first-line therapy re-
ceived the full six cycles of chemotherapy. This assumption
was a bias against more effective and more expensive treat-
ments (e.g., Cis/Pem and Carb/Pac/Bev). However, in clinical
practice, not all patients who respond would receive all six
cycles of first-line chemotherapy. Thus, a sensitivity analysis
was conducted on this assumption by reducing the cost of the
partial and complete response states in the fifth and sixth
treatment cycles. It was assumed that 50% of patients in
responding health states in cycles 5 and 6 would not receive
first-line chemotherapy and would not be charged for drug,
administration, or monitoring costs.
Additional sensitivity analyses included varying other
model assumptions in the base case such as changing the
3-week transition rate from end-of-life to death, excluding
bevacizumab single-agent maintenance therapy after com-
pleting triplet first-line therapy, and switching carboplatin
and cisplatin within regimens.
The cost-effectiveness of Cis/Pem was also evaluated
in a third patient population. The model compared costs and
consequences for Cis/Pem versus Cis/Gem, Carb/Pac, and
Carb/Pac/Bev in patients with adenocarcinoma or large cell
carcinoma only. This is a smaller subset of the base case
patient population, which also included patients with histol-
ogy not otherwise specified.
RESULTS
Results for the 2-year time horizon are presented. The
model found that approximately 80% of the total costs were
incurred within the first year, whereas survival into the
second year varied among treatments from less than 40% to
more than 50%. Most of the differences among treatments in
survival apparent at 1 year are gone by the end of the second
year. With only a minority of patients alive at the end of 2
years for all first line treatments, a longer time horizon is
unlikely to change the ICERs substantially.
Base case results in patients with nonsquamous NSCLC
(i.e., adenocarcinoma, large cell carcinoma, or not otherwise
specified) demonstrated using Cis/Pem as first-line chemo-
therapy added approximately 2.6 weeks of life (0.05 life-
years) compared with Cis/Gem and 3.6 weeks of life (0.07
life-years) to Carb/Pac at an additional cost of $4509 and
$12,631, respectively (Table 4). The ICER for Cis/Pem to
Cis/Gem measuring the incremental cost divided by the
incremental LYG was $83,537. The ICER for Cis/Pem to
Carb/Pac was $178,613 per LYG. Triplet first-line chemo-
therapy of Carb/Pac/Bev added 3.6 weeks of life compared
with Cis/Pem but at a substantial increase in cost. The
incremental cost per LYG was $337,179.
In the second population of patients with advanced
NSCLC with both squamous and nonsquamous histology, the
ICER for Cis/Pem to Cis/Gem was $104,577 per LYG. The
ICER for Cis/Pem to Carb/Pac was $231,291 per LYG.
At 2 years, the rankings of cost and effectiveness were
the same when quality-adjusted life-years were used instead
of life-years, but all ratios were about 50% higher (Tables 4
and 5). This indicates that with the short model timeframe
and relatively small differences in response, length of life and
costs are more important than quality of life for determining
the value of first-line therapy.
Sensitivity Analysis Results
Most reasonable changes in costs that were applied to
all treatments changed the ICER for Cis/Pem to Cis/Gem by
TABLE 4. Cost-Effectiveness and Cost-Utility for First-Line
Chemotherapy in Patients with Stage IIIB/IV Nonsquamous
NSCLC at 2 yra
Cost-Effectiveness Analysis Cost ($) Life-Years ICER ($) ICER ($)
Cis/Gem 61,008 0.9112
Carb/Pac 52,885 0.8945
Cis/Pem 65,517 0.9652
Carb/Pac/Bev 90,044 1.0379
Incremental Cis/Pem to Cis/
Gem
4509 0.0540 83,537
Incremental Cis/Pem to
Carb/Pac
12,631 0.0707 178,613
Incremental Carb/Pac/Bev to
Cis/Pem
24,528 0.0727 337,179
Cost-Utility Analysis Cost ($) QALYs ICUR ($) ICUR ($)
Cis/Gem 61,008 0.4676
Carb/Pac 52,885 0.4513
Cis/Pem 65,517 0.5016
Carb/Pac/Bev 90,044 0.5260
Incremental Cis/Pem to Cis/
Gem
4509 0.0339 132,829
Incremental Cis/Pem to Carb/
Pac
12,631 0.0503 250,992
Incremental Carb/Pac/Bev to
Cis/Pem
24,528 0.0244 1,006,065
a Includes patients with adenocarcinoma, large cell carcinoma, and other or not
otherwise specified histology.
Bev, bevacizumab; Carb, carboplatin; Cis, cisplatin; Gem, gemcitabine; ICER,
incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; Pac, pacli-
taxel; Pem, pemetrexed; QALY, quality-adjusted life-year.
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less than 10% (Figure 4). Pemetrexed is available in vials of
500 and 100 mg. Base case estimates primarily used the 500
mg vial; however, dosing using 100 mg vials for delivery of
pemetrexed may provide the most efficient dosing and has the
potential to eliminate wastage saving approximately $500 per
cycle. If all patients were average size (i.e., 1.8 m2), the
resulting ICER for Cis/Pem to Cis/Gem would be reduced to
$45,382 per LYG.
Further specifying the patient population to include
only those with advanced NSCLC with adenocarcinoma or
large cell carcinoma, yielded 2-year ICERs that were lower
than the base case results. Using Cis/Pem as first-line
chemotherapy in these patients added approximately 5.2
weeks of life (0.10 life-years) to Cis/Gem and Carb/Pac at
an additional cost of $7340 and $13,611, respectively. The
ICER for Cis/Pem to Cis/Gem was $72,325 per LYG. For
Cis/Pem to Carb/Pac, the cost per LYG was $132,547. The
ICER for Carb/Pac/Bev to Cis/Pem was more than
$650,000 per LYG.
In the base case analysis, costs of serious adverse events
were assumed to be equivalent for all regimens. This assumption
may have biased the ICERs against Cis/Pem considering fewer
serious adverse events have been observed with Cis/Pem com-
pared with Cis/Gem in advanced NSCLC.12 If serious adverse
event rates were increased for Cis/Gem or decreased for Cis/
Pem by 50%, the ICER of Cis/Pem to Cis/Gem would decrease
by 45 to 55% ($39,000–$44,000). An increase in the Cis/Pem
to Cis/Gem ICER of similar magnitude is seen if there is a
50% increase in adverse events with Cis/Pem or a 50%
decrease in Cis/Gem adverse events.
Another sensitivity analysis was conducted to address
the implied assumption in the model that almost all patients
who responded to first-line therapy received the full six
cycles of chemotherapy. When assuming that 50% of patients
in responding health states in cycles 5 and 6 did not receive
first-line chemotherapy, the resulting ICERs were $75,259 for
Cis/Pem to Cis/Gem, $164,904 for Cis/Pem to Carb/Pac, and
$316,600 Carb/Pac/Bev to Cis/Pem.
The dose of bevacizumab used also affected total
costs. In the base case, a recommended dose of 15 mg/kg
FIGURE 4. Effect of select assumptions and uncertainty in cost inputs in predicting the cost-effectiveness of cisplatin and
pemetrexed (Cis/Pem) compared with cisplatin/gemcitabine (Cis/Gem). This tornado diagram shows that most reasonable
changes in costs that were applied to all treatments changed the incremental cost-effectiveness ratio (ICER) for Cis/Pem to
Cis/Gem by less than 10%. LYG, life-year gained; NSCLC, non-small cell lung cancer; Pem, pemetrexed.
TABLE 5. Cost-Effectiveness of First-Line Chemotherapy in
All Patients with Stage IIIB/IV NSCLCa at Two yr
Cost-Effectiveness Analysis Cost ($) Life-Years ICER ($)
Cis/Gem 61,535 0.9102
Carb/Pac 50,283 0.8882
Cis/Pem 66,606 0.9587
Incremental Cis/Pem to Cis/Gem 5072 0.0485 104,577
Incremental Cis/Pem to Carb/Pac 16,323 0.0706 231,291
Cost-Utility Analysis Cost ($) QALYs ICUR ($)
Cis/Gem 61,535 0.4661
Carb/Pac 50,283 0.4469
Cis/Pem 66,606 0.4943
Incremental Cis/Pem to Cis/Gem 5072 0.0282 179,597
Incremental Cis/Pem to Carb/Pac 16,323 0.0475 343,870
a Includes both squamous and nonsquamous histology.
Carb, carboplatin; Cis, cisplatin; Gem, gemcitabine; ICER, incremental cost-
effectiveness ratio; ICUR, incremental cost-utility ratio; Pac, paclitaxel; Pem, pem-
etrexed; QALY, quality-adjusted life-year.
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was used for bevacizumab.24 If the dose of bevacizumab
could be reduced to 7.5mg/kg without decreasing effec-
tiveness, the ICER for Carb/Pac/Bev to Cis/Pem would
decrease from more than $300,000 to $128,390 per LYG.
The model was also sensitive to decreasing the dose of
gemcitabine from 1250 mg/m2 (as was used in the base
case) to 1000 mg/m2. Again, if reducing the dose of
Cis/Gem could be done without affecting effectiveness,
this change would increase the ICER for Cis/Pem to
Cis/Gem to $147,578 per LYG making Cis/Pem less cost-
effective. However, it is unclear what impact decreasing
the doses of bevacizumab or gemcitabine would have on
the effectiveness of these regimens; thus, the cost-effec-
tiveness benefits associated with these dose reductions
may be overestimated.
Changes to progression rate multipliers, or the rates at
which patients move from one disease state to another, can
have substantial effects on ICERs. The ICERs for Cis/Pem to
Cis/Gem vary from $58,349 to $177,481 if the progression
transition rates while on first-line chemotherapy were varied
from 50 to 200% of their original values. Similar multipliers
were applied to the transition rates between stable on chemo-
therapy and partial response health states. If the response
rates for Cis/Gem were doubled, then Cis/Pem becomes
dominated. However, doubling response rates for Cis/Pem
increased its advantage over Cis/Gem and decreased the
ICER to $44,419.
DISCUSSION
This study provides information on the cost-effective-
ness of Cis/Pem as first-line chemotherapy in patients with
stage IIIB/IV NSCLC compared with Cis/Gem and two other
widely used chemotherapy regimens. The main focus of this
study was to evaluate the cost-effectiveness of Cis/Pem
compared with Cis/Gem based on clinical trial data in a
patient population with advanced nonsquamous NSCLC.
Other comparisons between Cis/Pem and Carb/Pac or
Carb/Pac/Bev are secondary because they are based on an
indirect comparison of efficacy and not randomized phase
III clinical trials.
This study also emphasizes the importance of histology
in identifying the appropriate patient for Cis/Pem first-line
chemotherapy. Although Cis/Pem may or may not be con-
sidered cost-effective compared with Cis/Gem in all patients
with advanced NSCLC, the ICER for Cis/Pem to Cis/Gem
was lower (more cost-effective) in patients with nonsqua-
mous cell histology (i.e., adenocarcinoma, large cell, or
histology not otherwise specified). Cis/Pem is most cost-
effective against Cis/Gem in the smaller subset of patients
with adenocarcinoma or large cell carcinoma. This is partic-
ularly important, because approximately 70% of patients with
advanced NSCLC have nonsquamous histology including
adenocarcinoma, large cell carcinoma, or histology not oth-
erwise specified.12
The base case cost per LYG for Cis/Pem to Cis/Gem
may be considered cost-effective when compared with a
commonly mentioned threshold of $100,000 per LYG in the
United States. However, there is no documentation to support
this threshold in the medical literature, and it is often criti-
cized for being outdated and not taking into consideration
whether the treatments are for life-threatening conditions
such as cancer or for acute, less severe conditions such as
otitis media. The ICER for Cis/Pem to Cis/Gem may be
considered acceptable, when compared with the ICER for
adding bevacizumab to Carb/Pac, a commonly reimbursed
chemotherapy regimen in the United States.25
A limited number of cost-effectiveness and cost-utility
analyses have been conducted evaluating Cis/Gem or Carb/
Pac in advanced NSCLC.26–29 Comparing the results to the
current analysis is difficult due to differences in year of
publication, country, and perspective. Additionally, several
different comparators, including monotherapy and best sup-
portive care, have been used, and the results are not directly
comparable with the therapies included in this study. Plati-
num-containing doublets are currently considered to be the
standard of care for first-line chemotherapy.5 Thus, this anal-
ysis compares the incremental costs and benefits of a new
first-line therapy, Cis/Pem, to the most clinically relevant
first-line therapies in the United States.
A recent analysis by Grusenmeyer and Gralla25 evalu-
ated the cost-effectiveness of adding bevacizumab to carbo-
platin and paclitaxel in patients with advanced NSCLC.
Although the triplet added approximately 2.3 months to
median patient survival, it did so at an incremental cost of
$66,270. Adding bevacizumab to carboplatin and paclitaxel
yielded a cost of more than $340,000 per LYG and was not
considered cost-effective by the authors. Similar results were
demonstrated in this economic analysis, where the incremen-
tal cost-effectiveness of Carb/Pac/Bev to Carb/Pac from this
model, based on the efficacies for the indirect comparison
efficacy, calculates to $259,100. Based on the model results
and not a direct phase III comparison, first-line use of Cis/
Pem provides much of the survival benefit of Carb/Pac/Bev at
a lower price in patients with nonsquamous cell histology,
particularly in the subgroup of patients with adenocarcinoma
or large cell carcinoma.
None of the existing economic studies identified used
histology to identify a specific patient subpopulation in which
the study therapy provides the greatest clinical benefit and is
the most cost-effective. This study used prospective, head-
to-head clinical trial data demonstrating survival differences
based on histologic type. Results from this cost-effectiveness
analysis may help to guide the use of Cis/Pem in patients with
advanced nonsquamous NSCLC. Although Cis/Pem may or
may not be considered cost-effective in all patients with
NSCLC regardless of histology, it can be considered cost-
effective in those with nonsquamous cell histology and even
more so for patients with adenocarcinoma or large cell
carcinoma, specifically.
As with any economic analysis, there are limitations to
this study that may require additional research. The Cis/Pem
to Cis/Gem ICERs represent the main findings of this study
and provide the most robust data because they are based on
head-to-head clinical trial data. However, no head-to-head
clinical trial data are available comparing Cis/Pem with
Carb/Pac or Carb/Pac/Bev. Thus, the economic model is not
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based on data directly evaluating the impact of these first-line
chemotherapy regimens on patient outcomes, safety, and
costs within the same patient population. This limitation was
addressed using a mixed treatment comparison model or
evidence synthesis, which may provide the best data available
to date without conducting a randomized phase III clinical
trial. Because the response and survival data are based on a
phase 3 clinical trial that included only chemotherapy-naive
patients with stage IIIB or IV NSCLC with performance
status 0 or 1 (asymptomatic or symptomatic but completely
ambulant), inferences from the model results should be lim-
ited to this subpopulation.
A well-cited randomized study by the Eastern Coop-
erative Oncology Group evaluated the efficacy of four
first-line doublet therapies including Cis/Gem and Carb/
Pac in advanced NSCLC and found similar efficacy among
all regimens.2 Thus, if a head-to-head trial of Cis/Pem
versus Carb/Pac were to be conducted, it could be hypoth-
esized that Cis/Pem might be found noninferior to Carb/
Pac similar to the results of the recent head-to-head study
of Cis/Pem and Cis/Gem study by Scagliotti et al.12 in the
overall patient population. Furthermore, it could be hy-
pothesized that Carb/Pac would have similar efficacy to
Cis/Gem in nonsquamous patients because no histology
effect for either regimen has been previously reported.
However, the main shortcoming of this study is the lack of
a head-to-head clinical trial comparing the efficacy of
Cis/Pem with the triplet of Carb/Pac/Bev as first-line
therapy in advanced NSCLC.
Another limitation of this study was that with the
exception of first-line chemotherapy costs, direct NSCLC-
related costs included in the model are from a claims
database analysis whose data date back to 2002. General
limitations associated with database analyses exist includ-
ing potential diagnostic or procedural coding inaccuracies,
incomplete data, and lack of generalizability of findings to
other types of third-party payers (e.g., Medicare and Med-
icaid). Also, because the database represented medical
claims, it did not contain useful clinical data such as
histology, stage, performance status, or health status,
which may affect treatment costs. Additionally, because
Cis/Pem was not indicated for first-line chemotherapy
during the years covered in the database analysis and
bevacizumab has only been approved for first-line use in
advanced NSCLC since late 2006, there were very few
cases of patients treated with either of these two agents
within the database cost analysis.
Finally, this analysis is based on a U.S. payer perspec-
tive and is limited to direct lung-cancer related medical costs.
No accounting for direct nonmedical costs such as transpor-
tation or societal costs such as lost productivity or caregiver
costs is included. Thus, results may not be generalizable to all
health care systems or payers.
This study is the first to estimate the cost-effective-
ness of Cis/Pem as first-line therapy in advanced or met-
astatic NSCLC. Based on head-to-head clinical trial data in
patients with advanced nonsquamous NSCLC, Cis/Pem
provides better survival than Cis/Gem, which drives the
incremental cost-effectiveness. Additionally, this study
emphasizes the importance of histology in assessing the
incremental benefits and costs of Cis/Pem therapy. Cis/
Pem may be a cost-effective regimen for first-line chemo-
therapy in patients with stage IIIB/IV NSCLC, particularly
in patients whose histology is nonsquamous cell carci-
noma.
APPENDIX: MODEL ASSUMPTIONS
In this model, it was assumed that probabilities
change based on the cycle and current health state but not
previous health states. This is inherent in the semi-Markov
structure as only proportions of a cohort and not individual
patients were modeled. Also, consistent with confirmed
response in the clinical trial by Scagliotti et al.,12 health
states of partial response and complete response were not
reached until the beginning of the third cycle and fourth
cycle, respectively.
Side-effect probabilities were assumed to be inde-
pendent of health state and response, and progression
probabilities were assumed to be independent of side
effects. Overall rates of serious adverse events by treat-
ment cycle were obtained from clinical trial results. How-
ever, the data did not include the proportion of adverse
events that occurred in patients who were progressing,
responding, or remaining stable. Because this is a cohort
model, as long as the overall proportions of adverse events
are correct and adverse event costs are independent of
treatment or disease costs, not altering adverse event
probabilities by health state should have no effect on cost
results. Additionally, no dose reductions or delays between
chemotherapy cycles were modeled.
Because the focus of the model was to evaluate the
costs and effectiveness of first-line chemotherapy only,
costs and utilities for the health states without chemother-
apy were assumed to be equivalent regardless of the
first-line treatment used. Finally, state transition probabil-
ities beyond the first year were assumed to be the same for
all initial treatments.
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